Clinical Trials Logo

Filter by:
NCT ID: NCT04341285 Withdrawn - COVID-19 Clinical Trials

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

ECMO-VID
Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit. Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias. Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers

NCT ID: NCT04300075 Withdrawn - Clinical trials for Cranial Skull Base Bone Removal

The CUSA Clarity Bone Tip Study

Start date: June 2023
Phase:
Study type: Observational

The aim of the Study is to investigate the clinical performance and surgeon preferences of the CUSA Clarity Bone Tip during skull base surgery with removal of bony, and other cranial calcified tissue.

NCT ID: NCT04264806 Withdrawn - Clinical trials for Myelodysplastic Syndromes

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for Hematopoietic Stem Cell Transplantation (HSCT).

NCT ID: NCT04254380 Withdrawn - Clinical trials for Diabetes Mellitus, Type 1

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

GENTL 1
Start date: December 4, 2019
Phase: Phase 3
Study type: Interventional

Primary Objective: • To compare the immunogenicity of Gan & Lee Insulin Lispro Injection and EU-authorized Humalog following treatment in adult subjects with T1DM Secondary Objectives: - To evaluate the safety of Gan & Lee Insulin Lispro Injection in comparison with that of EU authorized Humalog following treatment in adult subjects with T1DM - To evaluate the efficacy of Gan & Lee Insulin Lispro Injection in comparison with that of EU authorized Humalog following treatment in adult subjects with T1DM

NCT ID: NCT04218019 Withdrawn - Clinical trials for Newly Diagnosed Glioblastoma in Patients =70 Years

Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation

GERAS
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to assess timing of TTFields use as well as safety, feasibility and preliminary efficacy of treatment with TTFields in elderly patients with newly diagnosed GBM simultaneous to RT/ CRT. The primary aim of the trial is to establish a safely conducted therapy rate higher than 0.8 in the treatment arm.

NCT ID: NCT04195373 Withdrawn - Clinical trials for Gastrointestinal Cancer

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Start date: November 23, 2020
Phase: Phase 1
Study type: Interventional

This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.

NCT ID: NCT04172363 Withdrawn - Chronic Wounds Clinical Trials

Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics

AntiSeptic
Start date: July 22, 2020
Phase: Phase 3
Study type: Interventional

The study objective is to improve the current and local standard antiseptic treatment by adjusting the antiseptic agent to the antimicrobial resistance testing result, accordingly. Currently, resistance testing will only be performed for the treatment with antibiotics.

NCT ID: NCT04158596 Withdrawn - Clinical trials for Chronic Rhinosinusitis Without Nasal Polyps

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

SDX-3101
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to assess the safety and efficacy of SDX-3101 for treatment of adult patients with chronic rhinosinusitis without nasal polyps (CRSsNP) by investigating a vibration pattern of SDX-3101 compared to a control

NCT ID: NCT04138485 Withdrawn - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Start date: December 20, 2019
Phase: Phase 2
Study type: Interventional

This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period. Eligible subjects will be randomized at Baseline in a 2:1 ratio of treatment IgPro10 or placebo in the DB Treatment Period. All subjects who enter OL Treatment Period will receive IgPro10.

NCT ID: NCT04096261 Withdrawn - Alzheimer Disease Clinical Trials

The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease

Start date: September 12, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of our study is the analysis of sleep phases and quality as well as the detection of respiratory pauses in subjects with cognitive disorder. To assess whether sleep quality is associated with the blood-brain barrier and Alzheimer's disease, which may be indicative of an early, non-invasively measurable change in brain activity in the early stages of Alzheimer's disease.